[(2R)-3-[[(2R)-2-azaniumyl-3-methoxy-3-oxopropyl]disulfanyl]-1-methoxy-1-oxopropan-2-yl]azanium;dichloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(2R)-3-[[(2R)-2-azaniumyl-3-methoxy-3-oxopropyl]disulfanyl]-1-methoxy-1-oxopropan-2-yl]azanium;dichloride
• 化学式: C8H18Cl2N2O4S2
• 分子量: 341.3
• InChiKey: QKWGUPFPCRKKMQ-USPAICOZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.21
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  155
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-methyl-hexa-2,3-dienenitrile 、 [(2R)-3-[[(2R)-2-azaniumyl-3-methoxy-3-oxopropyl]disulfanyl]-1-methoxy-1-oxopropan-2-yl]azanium;dichloride 、 sodium ethanolate 以63%的产率得到
  参考文献：
  名称：

  LANDOR, STEPHEN R.;LANDOR, PHYLLIS D.;SELIKI-MURUUMU, JOHN;FOMUM, Z. TANE+, J. CHEM. SOC. PERKIN TRANS. PT 1,(1988) N 7, C. 1759-1763

  摘要：

  DOI：

文献信息

• [EN] PHOTOALIGNING MATERIALS<br/>[FR] MATÉRIAUX DE PHOTOALIGNEMENT
  申请人：ROLIC AG

  公开号：WO2013050121A1

  公开（公告）日：2013-04-11

  The present invention relates to polymer, homo- or copolymer or oligomer for the photoalignment of liquid crystals, especially for the planar orientation of liquid crystals, comprising a main chain and a side chain, wherein the side chain and/or main chain comprises a polar group, compositions thereof, and its use for optical and electro optical devices, especially liquid crystal devices (LCDs).

  本发明涉及用于液晶的光调向的聚合物、同聚物或寡聚物，特别用于液晶的平面取向，包括主链和侧链，其中侧链和/或主链包含极性基团，以及其组合物，以及其在光学和电光设备中的应用，特别是液晶设备（LCD）。
• Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
  申请人：Nacuity Pharmaceuticals, Inc.

  公开号：US20190135741A1

  公开（公告）日：2019-05-09

  The present invention includes pharmaceutical composition comprising (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide)(diNACA) or D 3 -N-acetyl cysteine amide, or a physiologically acceptable salt thereof, having a deuterium enrichment above the natural abundance of deuterium, and derivatives or solids thereof, and methods of using diNACA to treat eye diseases and other diseases associated with oxidative damage including, e.g., antivenom, beta-thallassemia, cataract, chronic obstructive pulmonary disease, macular degeneration, contrast-induced nephropathy, asthma, lung contusion, methamphetamine-induced oxidative stress, multiple sclerosis, Parkinson's disease, platelet apoptosis, Tardive dyskinesia, Alzheimer disease, HIV-1-associated dementia, mitochondrial diseases, myocardial myopathy, neurodegenerative diseases, pulmonary fibrosis, skin pigmentation, skin in need of rejuventation, antimicrobial infection, Friedreich's ataxia.

  本发明包括含有（2R,2R′）-3,3′-二硫代二乙酰胺基丙酰胺（diNACA）或D3-N-乙酰半胱氨酸酰胺，或其生理可接受的盐的药物组合物，其氘富集程度高于氘的自然丰度，以及其衍生物或固体，以及使用diNACA治疗与氧化损伤相关的眼部疾病和其他疾病的方法，例如抗毒素、β地中海贫血、白内障、慢性阻塞性肺病、黄斑变性、造影剂诱导性肾病、哮喘、肺挫伤、甲基苯丙胺诱导的氧化应激、多发性硬化症、帕金森病、血小板凋亡、迟发性运动障碍、阿尔茨海默病、HIV-1相关性痴呆、线粒体疾病、心肌肌病、神经退行性疾病、肺纤维化、皮肤色素沉着、需要复活的皮肤、抗菌感染、弗里德里希氏共济失调。
• Cysteine derivatives
  申请人：AJINOMOTO CO., INC.

  公开号：US20020115723A1

  公开（公告）日：2002-08-22

  Objects of the present invention are to provide an oxidative stress inhibitor which is capable of suppressing the expression of a cytotoxic protein and the activation of a gene transcriptional regulatory factor taking part such expression of a cytotoxic protein and exhibits good feeling upon use and safety; to provide a method for preventing, retarding, alleviating or treating a skin change due to aging or an undesirable aesthetic skin change, both caused or promoted by an oxidative stress; and to provide a cosmetic composition or dermatologic preparation for external use comprising the oxidative stress inhibitor as an effective ingredient, and for those purposes are employed an oxidative stress inhibiting agent which comprises, as an effective ingredient, at least one selected from cysteine or cystine derivatives and the salts thereof.

  本发明的目的是提供一种能够抑制细胞毒蛋白表达和基因转录调节因子激活的氧化应激抑制剂，该抑制剂在使用时具有良好的感觉和安全性；提供一种预防、延缓、缓解或治疗由氧化应激引起或促进的皮肤老化或不良美容皮肤变化的方法；提供一种含有氧化应激抑制剂作为有效成分的用于外用的化妆品组合物或皮肤科制剂。为了实现这些目的，使用一种氧化应激抑制剂，其有效成分包括至少一种来自半胱氨酸或半胱氨酸衍生物及其盐的物质。
• [EN] COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS COMME INHIBITEURS DE LA CRISTALLISATION DE LA L-CYSTINE ET UTILISATIONS ASSOCIÉES
  申请人：UNIV NEW YORK

  公开号：WO2011062640A1

  公开（公告）日：2011-05-26

  A method of preventing or inhibiting L-cystine crystallization using the compounds of formula (I) is disclosed, wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.

  揭示了一种使用式(I)化合物预防或抑制L-半胱氨酸结晶的方法，其中A、L、R1a、R1b和m如本文所述。这些化合物可以制备为药物组合物，并可用于预防和治疗与L-半胱氨酸结晶有因果关系的病症，例如包括（但不限于）肾结石。
• COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF
  申请人：WARD Michael D.

  公开号：US20180305307A1

  公开（公告）日：2018-10-25

  A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: R 1a —[O] v -(-A-L-) m -A-[O] v —R 1b wherein A, L, R 1a , R 1b , m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.

  本发明揭示了一种防止或抑制L-半胱氨酸结晶的方法，使用公式I的化合物：R1a—[O]v-(-A-L-)m-A-[O]v—R1b，其中A、L、R1a、R1b、m和v如本文所述。这些化合物可以制备为药物组合物，并可用于预防和治疗与L-半胱氨酸结晶有因果关系的疾病，例如包括（但不限于）肾结石。